anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The influence of home obesogenic environments, as assessed by the validated Family Nutrition and Physical Activity (FNPA) tool, and child obesity during the COVID pandemic were evaluated using electronic health records in this retrospective cohort study.
METHODS: Historical data on BMI and the FNPA screening tool were obtained from annual well-child visits within the Geisinger Health System. The study examined youth ages 2-17 that had a BMI record and an FNPA assessment prior to the pandemic (BMI 3/1/19-2/29/20), 1 BMI record 3 months into the pandemic (6/1/20-12/31/20) and 1 BMI in the second year of the pandemic (1/1/21-12/31/21). Tertiles of obesity risk by FNPA score were examined. Mixed-effects linear regression was used to examine change in BMI slope (kg/m2 per month) pre-pandemic to pandemic using FNPA summary and subscales scores as predictors and adjusting for confounding factors.
RESULTS: The analyses included 6,746 children (males: 51.7%, non-Hispanic white: 86.6%, overweight:14.8%, obesity:10.3%, severe obesity: 3.9%; mean(SD) age: 5.7(2.8) years). The rate of BMI change in BMI was greatest from early pandemic compared to pre-pandemic for children in lowest versus highest tertiles of FNPA summary score (0.079 vs. 0.044 kg/m2), FNPA-Eating (0.068 vs. 0.049 kg/m2), and FNPA-Activity (0.078 vs. 0.052 kg/m2). FNPA summary score was significantly associated with change in BMI from the pre-pandemic to early pandemic period (p = 0.014), but not associated with change in BMI during the later pandemic period.
CONCLUSIONS: This study provides additional insight into the changes in the rate of BMI change observed among children and adolescents in the United States during the COVID-19 pandemic. The FNPA provides ample opportunity to continue our exploration of the negative impact of the COVID-19 pandemic on the longitudinal growth patterns among children and adolescents.
The study product or placebo will be applied twice daily on a clean and dry skin for 120 days. Follow "3-6-9 method" as follows: for babies (6 months to 24 months) use 3 pumps for the whole body (1 pump for face, 1 pump for trunk and arms and 1 pump for lower limbs), for children from 25 months: use 6 pumps for the whole body (1 pump for face, 3 pumps for trunk and arms and 2 pumps for lower limbs) and for children with height greater than 1.5 meters: use 9 pumps for the whole body (1 pump for face, 1 pump for chest, 1 pump for back, 1 pump per arm (x2) and 2 pumps per leg (x2). It will be applied from inclusion visit simultaneously with topical treatment in the following order: first the study product or placebo on the whole body followed by the topical treatment on the flare-up areas.
This inventino relates to prodn. of erythrocyte irritable factor/granulocyte colony irritable factor fusion protein by genetic engineering method. Combination of two genes by a section of polypeptiide to form expression granular by using method of sub-clone of erythrocyte irritable factor with granulacyte colony irritable factor and end reformation and using polymerase chain reaction, and transferring it into mammal cells and obtg. high efficiency expression. Said fusion protein has dual activities of erythrocyte irritable factor and granulocyle colony irritable factor. Compared with same dose of EPO and G-CSF monomer, said fusion protein has higher biological activity. Said invention EPO biological activity is 100000 U/mg, and G-CSF is 10000000 U/mg.
Patient will be asked to attain fowler's position by placing a pillow in front of his trunk to support a comfortable breathing pattern. Then, patient will be instructed to inhale through nose deeply until no more air can be inhaled and which will be followed by a slow expiration through pursed or rounded lip, like at the time of whistling.Patient will also be demonstrated visually for the proper breathing pattern even for once to multiple times till complete understanding before performing itself. The technique will be administered to the patient under supervision for 10 minutes, and the patient will be instructed to use this trained exercise in his daily routine as per needed.
PROBLEM TO BE SOLVED: To develop physiological action of pain stopping, inflammation reduction, etc., by adding modulation effect by a method wherein granite and magnetite are used as essential materials, and one or more kind of materials selected from coal, charcoal, malachite, zeolite, montmorillonite, lime stone, gypsum, talc, and silver is selectively contained. SOLUTION: 80wt.% of granite, and 10wt.% of magnetite are used as essential materials. Charcoal of broad-leaved tree of 15μm average particle size, silver of 5μm average particle size, and other materials of 300 mesh average particle size are arranged by a mixing ratio of 8wt.% of charcoal, 1wt.% of zolite, and 1wt.% of silver thereto to obtain a blended material being a modified material. The blended material 1 is filled in a container 10, which is hermetically sealed. The container 10 is charged into each 1 liter of tap water and distilled water, allowed to stand for a specific time, and the tap water is made into the same degree good quality water as mineral water on the market. Further, the distilled water is made into very excellent quality water.  In addition to modulation effect, a modified material for physiological action of stopping the pain, inflammation reduction, etc., can be developed.
BACKGROUND: Management of inferior ramus of the pubis-ischium ramus remains controversial, and related research is sparse. The main intention of this study is to describe the biomechanical and clinical outcomes of pubis-ischium ramus fractures in Tile B pelvic injuries and to identify the feasibility and necessity of fixation of the inferior ramus of the pubis-ischium ramus.
METHODS: This study comprised two parts: a biomechanical test and a retrospective clinical study. For the biomechanical tests, Tile B-type pelvic injuries were modeled in six cadaver specimens by performing pubis-ischium osteotomies and disruption of the anterior and interosseous sacroiliac ligaments. The superior and/or inferior rami of the pubis-ischium ramus were repaired with reconstruction plates and separated into three groups (A, B, and C). Specimens were placed in the standing position and were loaded axially with two-leg support for three cycles at 500 N. The displacements of sacroiliac joints at osteotomy were measured with Vernier calipers and compared using statistical software. To investigate the clinical outcomes of this technique, 26 patients were retrospectively analyzed and divided into a superior ramus fixation group (Group D) and a combined superior and inferior ramus of the pubis-ischium ramus fixation group (Group E). The main outcome measures were time of operation, blood loss, postoperative radiographic reduction grading, and functional outcomes.
RESULTS: In the vertical loading test, Group E showed better pelvic ring stability than Group D (P < 0.05). However, the shift of the sacroiliac joints was almost identical among the three groups. In our clinical case series, all fractures in Group E achieved bony union. Group E demonstrated earlier weight-bearing functional exercise (2.54 ± 1.45 vs 4.77 ± 2.09; P = 0.004), earlier bony union (13.23 ± 2.89 vs 16.55 ± 3.11; P = 0.013), and better functional outcomes (89.77 ± 7.27 vs 82.38 ± 8.81; P = 0.028) than Group D. The incidence of sexual dysfunction was significantly lower in Group E than that in Group D (2/13 vs 7/13; P = 0.039). Bone nonunion occurred in two patients in Group D, and two patients in Group E had heterotopic ossification. None of the patients exhibited wound complications, infections, implant failures, or bone-implant interface failures.
CONCLUSIONS: Fixation of the inferior ramus of a pubis-ischium ramus fracture based on conventional fixation of the anterior pelvic ring is mechanically superior in cadaveric Tile B pelvic injury and shows rapid recovery, good functional outcomes, and low incidence of complications.
1469398 Dental treatment ORAL HEALTH PRODUCTS INC 21 May 1973 [22 Feb 1972] 8144/72 Heading A5B Compositions for application to the teeth for the purposes of preventing calculus, removing plaque, removing caries and brightening teeth comprise an aqueous solution of N- monochloroglycine buffered to a pH of 8 to 12. The N-monochloroglycine may be prepared in situ from sodium, potassium or calcium hypochlorite and glycine. The buffer system may be glycine, sodium chloride and sodium hydroxide; an alkali metal phosphate e.g. disodium hydrogen, phosphate or a borate e.g. Na2B4O7. The compositions may be applied to the teeth in the form of a pulsating jet stream. The compositions may be in the form of a solid or paste dentifrice or a mouthwash. The composition may be an aqueous solution formed by addition of one or more tablets preferably effervescent to water or an aqueous solution.
PURPOSE: Metabolic dysfunction-associated steatohepatitis (MASH) is a liver disease that has gained widespread attention globally. Unfortunately, there is no approved treatment for this condition yet. However, recent research has identified Apoptosis signal-regulating kinase 1 (ASK1) and thyroid hormone receptor-β (THR-β) as potential targets for treating MASH. Although the individual effects of these two targets have been studied, their combinatory effect has not been well defined. Therefore, further research is needed to investigate the potential benefits of targeting both ASK1 and THR-β for treating MASH.
METHODS: We established a MASH model using the HFHFrC diet (high fat, high fructose, and cholesterol) and carbon tetrachloride (CCL4). Forty mice were evenly assigned to four groups: vehicle, GS4997 (an ASK1 inhibitor), MGL3196 (a THRβ agonist), GS4997+ MGL3196 combination (combo). The drugs were administered for 8 weeks, after which the mice were sacrificed for serum biochemical tests, liver TG and TC evaluation, liver histopathological study, and gene expression validation.
RESULTS: GS4997 and MGL3196, when used in combination, have been shown to have synergistic effects on various parameters. Firstly, they synergistically reduced body weight and liver body weight ratio. Secondly, this combination also synergistically lowered AST and TC. Thirdly, synergistic effects were also observed in liver TG and TC reduction. Fourthly, we further confirmed that GS4997 mildly improved liver inflammation, ballooning, and fibrosis, but exhibited incredible histopathological efficacy when combined with MGL3196. Finally, this combinatory effect can be interpreted by synergistically regulating lipid-related genes such as Dio1, Ctp1-α, and Cat, inflammation-related genes such as Il-6, Il-8, and Mcp-1, and fibrosis-related genes such as Tgf-β, Col1α1, and Col6α3.
CONCLUSION: GS4997 and MGL3196, when used in combination, have been shown to have a comprehensive effect on MASH by synergistically regulating lipid, inflammation, and fibrosis-related gene expression through co-targeting ASK1 and THRβ.
The product was the novel titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
Tobacco use is the single largest cause of premature and preventable death in the U.S. The prevalence of tobacco use among adults is currently highest among Alaska Natives. Over 50% of Alaska Native women residing in the Yukon-Kuskokwim (Y-K) Delta of western Alaska use smokeless tobacco or smoke cigarettes during pregnancy. Alaska Natives of this region are of Yup'ik or Cup'ik Eskimo, or Athabascan Indian ethnicity. No prior work has evaluated tobacco use interventions for pregnant Alaska Native women.

This proposal builds on our successful partnership and track record of collaboration with Y-K Delta Alaska Natives. The objective of this R21 proposal is to develop and pilot test a novel, culturally-tailored behavioral approach to tobacco cessation for pregnant Alaska Native women. We expect that as a result of this project, we will have developed a replicable, feasible, and acceptable counseling intervention, the efficacy of which can be tested in future larger-scale randomized clinical trials. Social cognitive (learning) theory is the conceptual basis for the proposed intervention.

This project will take place in two phases. In Phase 1, we will develop a multi-component, culturally-tailored, tobacco use intervention with and for Alaska Native pregnant women, including a videotape and telephone counseling. This work will include development of a counselor manual and development of the intervention with focus groups. During this phase, 10 pregnant women will complete the protocol, which will be modified and refined based on feedback from participants and counselors. Phase 2, consisting of a pilot clinical trial, will apply a randomized, two group design with assessments at the first prenatal visit (baseline) and at the last prenatal visit approximately 36 weeks gestation. Pregnant women will be recruited and randomized to either a standard (N=30) or enhanced (N=30) tobacco use intervention. The overall health related objective of this line of research is to develop effective treatment programs with and for Alaska Native pregnant women that will ultimately reduce the risk of tobacco-related disease.
The invention provides a swine Japanese encephalitis virus strain and application thereof, belonging to the field of biotechnology. The invention provides a swine Japanese encephalitis virus JEV-JS strain, and the microorganism collection number is CGMCC (China General Microbiological Culture Collection Center) NO. 4247. In addition, the invention provides a vaccine composition comprising the inactivated swine Japanese encephalitis virus JEV-JS strain and an acceptable adjuvant in veterinary pharmacy. The invention further provides the application of the swine Japanese encephalitis virus JEV-JS strain in preparation of medicaments for preventing diseases caused by swine Japanese encephalitis virus. The swine Japanese encephalitis virus JEV-JS strain disclosed by the invention is screened out from swine Japanese encephalitis prevalent virus strains separated from pig farms in various regions and can be used as the virus strain for producing an inactivated vaccine, and the virus strain has good immunogenicity and can be used as the virus strain for the vaccine. The prepared swine Japanese encephalitis inactivated vaccine disclosed by the invention can be used for preventing reproductive disorders of sows, orchitis of boars and other swine Japanese encephalitis diseases caused by the Japanese encephalitis virus.
Patients will receive CC-486 orally (PO) D1-14 of a 28-day cycle, in a similar fashion to the QUAZAR study for a minimum of 4 cycles. Patients that achieve a response (CR or PR) will remain on study for a maximum of 12 months. Patients without a response at 4 months will come off the study.
The capacity of lymphocytes continuously home to lymphoid structures is remarkable for cancer immunosurveillance and immunotherapy. Lymphocyte homing and recirculation within the tumor microenvironment (TME) are now understood to be adaptive processes that are regulated by specialized cytokines and adhesion molecule signaling cascades. Restricted lymphocyte infiltration and recirculation have emerged as key mechanisms contributing to poor responses in cancer immunotherapies like chimeric antigen receptor (CAR)-T cell therapy and immune checkpoint blockades (ICBs). Uncovering the kinetics of lymphocytes in tumor infiltration and circulation is crucial for improving immunotherapies. In this review, we discuss the current insights into the adhesive and migrative molecules involved in lymphocyte homing and transmigration. The potential mechanisms within the TME that restrain lymphocyte infiltration are also summarized. Advanced on these, we outline the determinates for tertiary lymphoid structures (TLSs) formation within tumors, placing high expectations on the prognostic values of TLSs as therapeutic targets in malignancies.
Subjects first inhaled active comparator Xe-133, approximately 10 to 30 millicuries (mCi), and ventilation planar scintigraphy was performed per site standard of care procedures for subject medical need. On the same day, following completion of Xe-133 imaging, subjects inhaled experimental Technegas (Technetium-99m labeled carbon particles), approximately 1.1 mCi, and ventilation planar scintigraphy was performed.
Carcinogenesis

Studies in animals to evaluate the carcinogenic potential of cipaglucosidase alfa-atga have not been conducted. For information on an evaluation of carcinogenicity of miglustat in animals, see the Opfolda Prescribing Information.

Mutagenesis

Studies to evaluate the mutagenic or genotoxic potential of cipaglucosidase alfa-atga have not been conducted. For information regarding the mutagenesis of miglustat, see the Opfolda Prescribing Information.

Impairment of Fertility

In a fertility study in rats, cipaglucosidase alfa-atga (75, 150, or 400 mg/kg) was administered intravenously to male and female rats every other day. Dosing in males was initiated 28 days prior to cohabitation with untreated females. Dosing in females was initiated 14 days prior to cohabitation with untreated males and continued through GD 7. Additional experimental groups received 60 mg/kg oral miglustat alone, or in combination with intravenous cipaglucosidase alfa‑atga 400 mg/kg, with the same frequency over the same pre‑mating interval (males) or pre-mating and pregnancy interval (females).

There was no effect on male or female rat fertility in any experimental group. Treatment of male rats with the combination was associated with increased preimplantation loss that was reversible. Treatment of female rats with the combination, or with miglustat alone, resulted in preimplantation loss; whether this would be reversible if treatment were discontinued prior to cohabitation is unknown. NOAELs were not identified for the combination in either male or female rats. The LOAEL margins for these doses represent 27-fold and 4-fold the MRHD of POMBILITI and Opfolda, respectively, based on plasma AUC exposure.
The invention provides isolated anti-prostate stem cell antigen (PSCA) antibodies that internalize upon binding to PSCA on a mammalian in vivo. The invention also encompasses compositions comprising an anti-PSCA antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PSCA antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PSCA antibodies. The invention encompasses a method of producing the anti-PSCA antibodies. Other aspects of the invention are a method of killing a PSCA-expressing cancer cell, comprising contacting the cancer cell with an anti-PSCA antibody and a method of alleviating or treating a PSCA-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PSCA antibody to the mammal.
The invention relates to a cyclophilin-threo-tyrosol-isoleucyl-phenylpropanoid (Trp-Thr-Tyr-Ile-Phe cyclopeptide) with hepatoma cytotoxicity and alpha-glucosidase inhibitory activity and a preparation method thereof, belonging to the technical field of extraction and preparation of biological products. The cyclic color-threo-tyro-isoleucyl-phenylpropanoid is fifteen-membered cyclic pentapeptide formed by connecting tryptophan, threonine, tyrosine, isoleucine and phenylalanine through an amide bond. This is a novel compound and has not been reported in the literature. The compound can be obtained by culturing frog-feces mould, and then extracting and separating. The pure product of the cyclophosphamide-threo-tyrosol-isoleucyl peptide is white powder, and the half inhibition concentration (IC  50 ) of the cycloparaffin-threo-tyrosol-isoleucyl peptide on liver cancer cells HepG2 is as follows: 29.80 μg/mL, half inhibitory concentration (IC  50 ) of alpha-glucosidase: 99.76. Mu.g/mL. The compound can be used as potential medicine for treating liver cancer and slimming medicine.
Patterns of microRNA (miRNA) expression are correlated to the degrees of tumor cell differentiation in human prostate cancer. MiRNAs can complementarily bind to either oncogenes or tumor suppressor genes, resulting in targeted gene silencing and thus changes of cellular tumorigenecity. Using miRNA microarray analysis, 8 down-regulated and 3 up-regulated known miRNAs in androgen-independent human prostate cancer cell lines, such as LNCaP C4-2B and PC3, compared to those androgen-dependent cell lines, such as LNCaP and PC3-AR9 were consistently detected. Fluorescent in-situ hybridization assays in human prostate cancer tissue arrays containing sixty patients at different stages also showed the same miRNA expression patterns in hormone-refractory prostate carcinomas (HRPC) compared to androgen-sensitive non-cancerous prostate epithelium. In-vitro tumorigenecity assays using one of the identified miRNAs, mir-146a, were performed to provide validation of its function in prostate cancer. Gain-of-function transfection of mir-146a markedly suppressed its targeted ROCK1 gene expression in androgen-independent PC3 cells, consequently resulting in reduced cancer cell proliferation, invasion and metastasis to human bone marrow endothelial cell monolayers. Since ROCK1 is the key kinase for activating hyaluronan-mediated HRPC transformation in vivo and in PC3 cells, mir-146a should function as a tumor-suppressor gene in modulating the ROCK1-associated tumorigenecity.
The present invention relates to a composition for skin regeneration, anti-wrinkling, antioxidant, anti-inflammatory and skin whitening effects. According to the present invention, cholic acid promotes collagen generation of fibroblasts and thus has effects of regenerating skin and reducing wrinkles. Cholic acid inhibits generation of free radicals and thus has an antioxidant effect. In addition, cholic acid inhibits generation of NO and thus has an anti-inflammatory effect. Cholic acid also inhibits synthesis of melanin and thus has a skin whitening effect. Therefore, the composition can be used as a pharmaceutical composition, an external use skin formulation, a cosmetic composition, or health food. The composition includes a compound represented by chemical formula 1 as an active ingredient.
FIELD: medicine. ^ SUBSTANCE: invention belongs to medicine, notably to experimental gastroenterology and refers to toxic chronic hepatitis treatment. Laboratory animals with pattern of toxic chronic hepatitis are administered intraperitoneal hyaluronidase injections at the rate of 1000 CU/kg. Injection is made once a day two days running. ^ EFFECT: method increases quantity of regional progenitor cells in hepatic tissue, providing significant hepatotropic effect and, as consequence, quick restitution of functionally active hepatic tissue. ^ 4 tbl, 2 ex
Patients receive temozolomide PO QD on days 1-5 of each cycle. Cycles repeat every 28 days for up to 6 cycles per standard of care in the absence of disease progression or unacceptable toxicity. Patients complete alternating telehealth assessment visits and in-person assessment visits after each cycle of treatment.